Comparison of iohexol 300 mg I/ml and Hexabrix 320 mg I/ml in central angiography. A double-blind trial.
Iohexol 300 mg I/ml and Hexabrix 320 mg I/ml have been compared in a randomized, double blind, parallel study, to evaluate hemodynamic parameters, diagnostic information and adverse reactions. A total of 55 patients entered the study, one of them was later excluded, because both contrast media were given by mistake. In the included material, 21 patients were given iohexol 300 mg I/ml in 55 selective injections, and 23 patients Hexabrix 320 mg I/ml in 65 selective injections. The median total dose was 52 (12-88) ml in the iohexol group and 51 (13-118) ml in the Hexabrix group. No changes in heart rate were seen. Angiograms of good or excellent quality were obtained, and no difference between the two media was shown. No serious adverse reaction occurred, and no statistical significant difference was found between the two media with respect to subjective patient reactions. The results indicate that the non-ionic, low-osmotic contrast medium iohexol is well tolerated in cerebral angiography with respect to the parameters tested. No statistical significant difference was found in any of these parameters between iohexol and Hexabrix.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002533:Cerebral Angiography; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000633:toxicity*; D004311:Double-Blind Method; D004562:Electrocardiography; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007463:Iodobenzoates / Q000633:toxicity*; D007472:Iohexol; D007485:Ioxaglic Acid; D010146:Pain / Q000209:etiology; D011897:Random Allocation; D012677:Sensation / Q000187:drug effects; D014283:Triiodobenzoic Acids / Q000633:toxicity*
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol; D007485:Ioxaglic Acid